Efficacy and Safety of a Combination of Thrombopoietin Receptor Agonist with an Immunosuppressant Therapy for the Management of Multirefractory Adult ITP: Results from a Retrospective, Multicenter, Observational Study

Etienne Crickx (1) , Guillaume Moulis (2) , Marc Ruivard (3) , Bouchra Asli (4) , Jean Pierre Marolleau (5, 6) , Mikael Ebbo (7) , Etienne Riviere (8) , Sylvain Audia (9) , Louis Terriou (10, 11) , Marc Michel (12) , Bertrand Godeau (12) , Matthieu Mahevas (13)

1 Hôpital Henri Mondor
2 CIC 1436 - Centre d'investigation clinique de Toulouse
3 CHU Estaing [Clermont-Ferrand]
4 Centre Hospitalier Edouard Herriot-Lyon
5 CHU Amiens-Picardie
6 HEMATIM - HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666
7 TIMONE - Hôpital de la Timone [CHU - APHM]
8 UCL - Université Catholique de Louvain = Catholic University of Louvain
9 Service de médecine interne et immunologie clinique (SOC 1) [CHU de Dijon]
10 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
11 Hôpital Claude Huriez [Lille]
12 CIC Henri Mondor - Centre d'Investigation Clinique Henri Mondor
13 U955 Inserm - UPEC - IMRB - "Transfusion et Maladies du Globule Rouge" [Créteil]

Domaines: Sciences du Vivant [q-bio]

Etienne Crickx, Guillaume Moulis, Marc Ruivard, Bouchra Asli, Jean Pierre Marolleau, et al.. Efficacy and Safety of a Combination of Thrombopoietin Receptor Agonist with an Immunosuppressant Therapy for the Management of Multirefractory Adult ITP: Results from a Retrospective, Multicenter, Observational Study. Blood, 2020, 136 (1), ⟨10.1182/blood-2020-143031⟩. ⟨hal-03604937⟩